TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2938394
Drug: Fentanyl (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (5 micrograms/kg) and pancuronium (0.07 mg/kg)
Study: 27831635
Drug: Short GnRH
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short GnRH agonist protocol
Study: 27831635
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate plus FSH and antagonist
Study: 25335325
Drug: Jiangtang Xiaozhi
Normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiangtang Xiaozhi Capsule (JTXZC), 4 pills three times per day for 8 weeks
Study: 25335325
Drug: Pioglitazone Tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone Tablet, 15 mg once daily for 8 weeks
Study: 18199700
Drug: Presumptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presumptive treatment
Study: 15928281
Drug: Complicated grief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complicated grief treatment
Study: 12869086
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (n=45)
Study: 8931917
Drug: Haloperidol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.5 mg, intravenously)
Study: 26905703
Drug: Esmolol 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 50 mg
Study: 7008800
Drug: levamisole 150
Normalized name: levamisole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: levamisole 150 mg weekly
Study: 28270226
Drug: Adipose-derived mesenchymal
Normalized name: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose-derived mesenchymal stem cells (ASC) administered to the submandibular glands
Study: 28270226
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered to the submandibular glands
Study: 26451726
Drug: Both supplement
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both supplement groups
Study: 19207345
Drug: computer-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: computer-based treatment
Study: 17987226
Drug: HPV L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV L1 VLP vaccines
Study: 12772885
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, plus a 5‐day continuous infusion of 750 mg/m2 5‐fluorouracil (FU; TCF)
Study: 12772885
Drug: docetaxel 85
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 85 mg/m2 plus cisplatin 75 mg/m2 (TC)
Study: 9850487
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment policy with sulfonylurea
Study: 9850487
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment policy with metformin
Study: 9850487
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment policy with insulin
Study: 9850487
Drug: Conventional policy
Normalized name: Polivy
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conventional policy (diet therapy)
Study: 338105
Drug: Fluorouracil, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil, 1 g daily, as a continuous infusion into the portal venous system during the first seven days after operation.
Study: 26218029
Drug: Implant-supported fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported fixed prostheses
Study: 21524765
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 160 mg/bid for 8 weeks
Study: 18056769
Drug: Cyclical oral
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical oral contraception (21‐d active/7‐d placebo for six consecutive 28‐d cycles)
Study: 18056769
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral contraception (168‐d active pill)
Study: 12698777
Drug: Oral hydration
Normalized name: terpin hydrate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydration (2L of water daily)
Study: 11200750
Drug: Immunochromatographic assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochromatographic assay detecting IgG antibodies against antigen 38 kDa (Rapid Test TB)
Study: 1281729
Drug: Terazosin (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (2, 5 or 10 mg)
Study: 6373442
Drug: Piretanide 6
Normalized name: piretanide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide 6 mg b.i.d.
Study: 6373442
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 25 mg b.i.d.
Study: 6373442
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 50 mg b.i.d.
Study: 31343273
Drug: Psychiatric medications
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric medications (n=21)
Study: 31343273
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n=35)
Study: 28320323
Drug: Rocuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium administered with closed-loop feedback infusion system in group laparoscopy
Study: 28320323
Drug: Rocuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium administered with closed-loop feedback infusion system in group control
Study: 24634065
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) delivered in groups
Study: 19765815
Drug: Mefloquine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (125 mg)
Study: 19765815
Drug: Sulfadoxine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine (250 mg) plus pyrimethamine (12.5 mg)
Study: 19765815
Drug: Chlorproguanil (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorproguanil (15 mg) plus dapsone (18.75 mg)
Study: 11208630
Drug: Regular inhaled
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular inhaled albuterol (100 microg per puff, in 2 puffs four times daily)
Study: 9565263
Drug: IMZ implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMZ implants connected by a Dolderbar
Study: 8667280
Drug: Transmandibular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmandibular implant (TMI)
Study: 3421513
Drug: Intravenous atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atenolol (0.05 and 0.10 mg/kg)
Study: 3421513
Drug: Oral atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral atenolol (50 and 100 mg)
Study: 25588408
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment with donepezil only)
Study: 17318860
Drug: New adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: New adjuvanted hepatitis B vaccine
Study: 17318860
Drug: Conventional vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional vaccine (booster)
Study: 9680894
Drug: alpha-tocopherol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-tocopherol (50 mg per day)
Study: 9680894
Drug: beta-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-carotene (20 mg per day)
Study: 7976797
Drug: Dimethindene maleate
Normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethindene maleate (DMM) 4 mg
Study: 7976797
Drug: Dimethindene maleate
Normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethindene maleate (DMM) 8 mg
Study: 28150423
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetyl hexapeptide‐3 with tripeptide‐10 citrulline (Group G1)
Study: 21921843
Drug: Lipiodol (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipiodol (doxorubicin 30 mg/m plus cisplatin 100 mg/m with lipiodol emulsification)
Study: 21921843
Drug: Solution (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution (doxorubicin 30 mg/m plus cisplatin 100 mg/m without lipiodol emulsification)
Study: 14695863
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 300,000 units of vitamin D(2)
Study: 14695863
Drug: Injected vitamin
Normalized name: vitamin A Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected vitamin D(2) plus 1 g/day oral calcium
Study: 14695863
Drug: 800 units/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 units/day oral vitamin D(3) plus 1 g/day calcium
Study: 11573063
Drug: Glucose 50%
Normalized name: glucose 50% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 50% solution
Study: 11573063
Drug: Sucrose 33%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose 33% solution
Study: 11573063
Drug: Sucrose 50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose 50% solution
Study: 9724481
Drug: Intravenous prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prostaglandin E1 (PGE1) administered by continuous infusion at a dose of 10 to 40 microg/h as tolerated
Study: 7663659
Drug: rhDNase twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase twice daily
Study: 3057041
Drug: Azelastine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 2.0 mg twice daily
Study: 3057041
Drug: Azelastine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 0.5 mg and 1.0 mg
Study: 3057041
Drug: Chlorpheniramine 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 4.0 mg four times daily
Study: 3057041
Drug: Azelastine (high-dose)
Normalized name: azelastine Metered Dose Nasal Spray
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine (high-dose)
Study: 31899602
Drug: Ubrogepant 150
Normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ubrogepant 150 mg daily for 28 days
Study: 31899602
Drug: Ubrogepant (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubrogepant (100-400 mg single and multiple ascending doses)
Study: 26440829
Drug: Home-based pulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based pulmonary rehabilitation (education about the disease, diet therapy, stress reduction methods, effective cough, breathing exercises, muscle stretching exercises) practiced at home three times per week for 7 weeks.
Study: 26440829
Drug: Routine visits
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine visits and weekly telephone follow-up (Control group).
Study: 23436437
Drug: N. sativa
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. sativa oil (2.5 mL, two times a day for 8 weeks)
Study: 23436437
Drug: Placebo (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2.5 mL, two times a day for 8 weeks)
Study: 16683383
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation radiation therapy (CFRT)
Study: 16683383
Drug: CFRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFRT plus concomitant chemotherapy (CT)
Study: 8279248
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with Diclofenac
Study: 24424073
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol 5000 IU daily for 28 days
Study: 24290111
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 150,000 IU cholecalciferol
Study: 22024477
Drug: Preoperative inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative inhalation of milrinone (Mil group)
Study: 16353851
Drug: Mapping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mapping therapy for sentence production
Study: 8270443
Drug: External-beam radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: External-beam radiation therapy plus 5-fluorouracil (5-FU)
Study: 8270443
Drug: External-beam radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: External-beam radiation therapy plus hycanthone (HYC)
Study: 2913977
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin with dihydroergotamine (A)
Study: 2913977
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin with dihydroergotamine (B)
Study: 4601222
Drug: 26° ‐adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26° ‐adapted RSV vaccine (28 children)
Study: 31174514
Drug: Screen-Refer-Treat (SRT)
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screen-Refer-Treat (SRT) model including universal Stage 1 ASD screening, immediate referral to community-based EI program, and provision of evidence-based ASD-specialized treatment.
Study: 15143716
Drug: Xuesaitong capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuesaitong capsule (PNS)
Study: 14999615
Drug: GBS type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS type V CPS‐tetanus toxoid (TT) vaccine
Study: 14999615
Drug: GBS type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS type V CPS‐cross‐reactive material (CRM(197)) conjugate vaccine
Study: 10355575
Drug: Ibandronate 50
Normalized name: ibandronic acid 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 50 mg
Study: 10355575
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg
Study: 10355575
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg
Study: 10355575
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg
Study: 10355575
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg
Study: 8955653
Drug: 5‐FU 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 10 mg/m2 orally
Study: 8955653
Drug: 5‐FU 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 10 to 25 mg/m2/d orally for 5 days with 776C85 3.7 mg/m2/d orally
Study: 8955653
Drug: 776C85 3.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 776C85 3.7 mg/m2/d orally
Study: 8955653
Drug: 5‐FU oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU oral route
Study: 7043497
Drug: Neurotropic drug
Normalized name: neurotrophin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotropic drug (tamitinol dihydrochloride coated tablets of 300 mg t.i.d.)
Study: 30916527
Drug: Wrist joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wrist joint splinting combined with physical therapy
Study: 26991616
Drug: Single-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose group (15 mg/kg TXA before surgery and saline 3 hours later)
Study: 26991616
Drug: 2-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose group (10 mg/kg TXA before and 10 mg/kg TXA 3 hours after surgery)
Study: 23177418
Drug: Single-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose group
Study: 26991616
Drug: 2-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose group
Study: 24289892
Drug: Fluoxetine (40mg/day)
Normalized name: fluoxetine 40 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (40mg/day)
Study: 21604039
Drug: Arthroscopic implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic implant removal
Study: 21604039
Drug: Open implant
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open implant removal
Study: 31074178
Drug: Anamorelin 5
Normalized name: Anamorelin
DrugBank: Anamorelin (DB06645)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Anamorelin 5 mg
Study: 31074178
Drug: Anamorelin 25
Normalized name: Anamorelin
DrugBank: Anamorelin (DB06645)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Anamorelin 25 mg
Study: 31074178
Drug: Anamorelin 25
Normalized name: Anamorelin
DrugBank: Anamorelin (DB06645)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Anamorelin 25 mg and 50 mg
Study: 26742380
Drug: Commercial anti-fogging
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial anti-fogging solution (Ultrastop®)
Study: 26742380
Drug: Baby shampoo
Normalized name: BABY SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baby shampoo solution (Johnson's® no more tear®)
Study: 23002172
Drug: Oral Appliances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Appliances (OAs)
Study: 21219381
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (EPA and DHA), 1.84 g per day for 32 weeks
Study: 19633072
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with MetS with insulin resistance (IR)
Study: 14985485
Drug: Infliximab maintenance
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab maintenance therapy (5 mg/kg every 8 weeks)
Study: 11527647
Drug: Echocardiography with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echocardiography with harmonic imaging and contrast injection
Study: 11527647
Drug: Echocardiography without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Echocardiography without contrast injection
Study: 11527647
Drug: Echocardiography with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echocardiography with contrast injection
Study: 9481960
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg acetaminophen with 10 mg hydrocodone
Study: 9481960
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ketoprofen
Study: 3105913
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) at a dosage of 1.75 mg/kg given over 12 hr (0.75 mg/kg over 1 hr, 0.5 mg/kg over 4 hr, and 0.5 mg/kg over 7 hr)
Study: 2858711
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human tissue-type plasminogen activator (rt-PA)
Study: 31077582
Drug: BT-11 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT-11 (up to 100 mg/kg, p.o.)
Study: 31077582
Drug: BT-11 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT-11 (up to 100 mg/kg daily for seven days, orally)
Study: 31077582
Drug: BT-11 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT-11 (multiple ascending doses)
Study: 31077582
Drug: BT-11 (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT-11 (0.01 µM ex vivo treatment)
Study: 30915987
Drug: PNK (paracetamol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNK (paracetamol, nefopam, ketoprofen)
Study: 28214613
Drug: Standardized skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized skin care regimens (body wash and twice daily applications of leave-on products for eight weeks)
Study: 23470803
Drug: High-dose DRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DRI (300 mg per day)
Study: 23470803
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (standard dose DRI 150 mg + hydrochlorothiazide 12.5 mg)
Study: 23470803
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose DRI (150 mg)
Study: 17060046
Drug: Pentoxifylline (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (continuous infusion of 1.5 mg/kg per hour during operation)
Study: 13129633
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (including radiation treatment alone)
Study: 10638985
Drug: Cimetidine (H2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (H2 antagonist), preoperative administration, dosage and duration not specified
Study: 10638985
Drug: Cimetidine (H2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (H2 antagonist), preoperative administration
Study: 9344321
Drug: High-dose rTNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rTNF alpha + interferon-gamma + melphalan
Study: 2863393
Drug: Intracorporeal injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracorporeal injection of 5 mg phentolamine
Study: 28793884
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (control group)
Study: 20803065
Drug: FEC90 ×4
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC90 ×4 cycles followed by eight doses of weekly paclitaxel (T)
Study: 17009401
Drug: S-pantoprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-pantoprazole (20 mg once a day)
Study: 17009401
Drug: racemic pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: racemic pantoprazole (40 mg once a day)
Study: 15213583
Drug: Methylphenidate plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate plus multimodal psychosocial treatment (including social skills training)